In India, it is recommended to include screening programs for treatable disorders like CH, CAH, G6PD, galactosemia (GALT), biotinidase, CF, and hemoglobinopathy variations such as sickle cell disease in target populations. This evidence concerns the gene GALT and galactosemia.